TG Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 02/04/2023
TG Therapeutics Stock Forecast and Price Target
The average price target for TG Therapeutics's stock set by recognized analysts recently is $19.00, which would result in a potential upside of approximately 9.45% if it reached this mark. The estimation is based on a high estimate of $40.00 and a low estimate of $4.00.
9.45% Upside
TG Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
TG Therapeutics's Price has grown In the last two years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $17.16 – an increase of 100.00%. For the next nine years, experts predict that TG Therapeutics's Fair Value will grow at a rate of 100.00%.
TG Therapeutics Revenue Forecast for 2023 - 2025 - 2030
TG Therapeutics's Revenue has grown In the last two years, rising from $150.00k to $6.69M – a growth of 4360.00%. In the next year, 0 analysts estimate that TG Therapeutics's Revenue will decrease by 65.17%, reaching $2.33M. According to professional forecasts, in 2030, TG Therapeutics's Revenue will decrease by 34.77%, reaching $4.36M.
TG Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, TG Therapeutics's Free Cash Flow has grown, moving from $-132.94M to $-296.03M – an increase of 122.68%. 0 analysts predict TG Therapeutics's Free Cash Flow will decrease by 30.99% in the next year, reaching $-204.29M. By 2030, professionals predict that TG Therapeutics's Free Cash Flow will decrease by 24.91%, to $-222.30M.
TG Therapeutics Net Income Forecast for 2023 - 2025 - 2030
In the last two years, TG Therapeutics's Net Income has grown by 101.37%, rising from $-172.87M to $-348.10M. In the following year, 0 experts forecast that TG Therapeutics's Net Income will decrease by 25.87%, to $-258.06M. In 2030, professionals predict that TG Therapeutics's Net Income will decrease by 21.41%, to $-273.56M.
TG Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, TG Therapeutics's EBITDA has seen an increase, rising from $-168.96M to $-344.49M. This represents a growth of 103.89%. For the following year, the 0 analysts predict that TG Therapeutics's EBITDA will drop by 26.48%, reaching $-253.26M. In 2030, the professionals' prediction is that TGTX's EBITDA will decrease by 21.85%, reaching $-269.21M.
TG Therapeutics EBIT Forecast for 2023 - 2025 - 2030
TG Therapeutics's EBIT has seen growth In the last two years, going from $-169.06M to $-344.77M – a gain of 103.93% In the following year, the 0 analysts surveyed believe that TG Therapeutics's EBIT will decrease by 26.50%, reaching $-253.39M. According to professionals, by 2030, TG Therapeutics's EBIT will have decreased by 21.86%, falling down to $-269.41M.
TG Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
TG Therapeutics's EPS has grown In the last two years, rising from $-1.96 to $-2.63 – a growth of 34.18%. In the next year, 0 analysts estimate that TG Therapeutics's EPS will decrease by 11.66%, reaching $-2.32. According to professional forecasts, in 2030, TG Therapeutics's EPS will decrease by 10.44%, reaching $-2.36.